Skip to main content
. 2021 Oct 14;11(10):1084. doi: 10.3390/life11101084

Figure 4.

Figure 4

VV-GMCSF-Lact antitumor efficacy against human glioblastoma in vivo. The data represent the mean ± SD of six mice. Arrows indicate the days of the drug injections. (A) U343 MG subcutaneous tumor volumes were decreased after i.t. treatment with VV-GMCSF-Lact. ** p < 0.01. (B) No effective inhibition of U87 MG subcutaneous tumor growth was achieved 21 days after treatment. ns: non-significant. (C) Growth of U87 MG subcutaneous tumors was inhibited after the fourth i.t. VV-GMCSF-Lact injection. *** p < 0.001. (D) MG4ns subcutaneous tumor volumes were decreased after i.t. treatment with VV-GMCSF-Lact. *** p < 0.001.